/

Sociétés

Bi

Non vérifié

Biogen Inc.

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieFinanceManagement/Organisation d'EntrepriseMédecine Santé Bien-être

74 communiqués de presse

Voir tous les communiqués de presse

17/09/2026

Biotechnologie

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

Source

Émetteur

1.00

0

03/09/2026

Biotechnologie

Management/Organisation d'Entreprise

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Source

Émetteur

1.00

0

01/09/2026

Biotechnologie

Médecine Santé Bien-être

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Source

Émetteur

1.00

0

06/08/2026

Biotechnologie

Médecine Santé Bien-être

Biogen Completes Acquisition of RayThera Inc.

Source

Émetteur

1.00

0

15/07/2026

Biotechnologie

Biogen Appoints Michael J. Parini as Chief Legal Officer

Source

Émetteur

1.00

0

29/06/2026

Biotechnologie

Médecine Santé Bien-être

Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

Source

Émetteur

1.00

0

17/06/2026

Biotechnologie

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Source

Émetteur

1.00

0

04/06/2026

Biotechnologie

Annonces Économiques

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

Source

Émetteur

1.00

0

03/06/2026

Biotechnologie

Médecine Santé Bien-être

Annonces Économiques

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Source

Émetteur

1.00

0

14/05/2026

Biotechnologie

Médecine Santé Bien-être

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0